Home › Compare › DELTF vs ABBV
DELTF yields 2.21% · ABBV yields 3.06%● Live data
📍 DELTF pulled ahead of the other in Year 4
Combined, DELTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DELTF + ABBV for your $10,000?
Delta Galil Industries Ltd. engages in the design, development, production, marketing, and sale of apparel products worldwide. It operates through five segments: Delta USA, Global Upper Market, Delta European Brands, Delta Premium Brands, and Delta Israel. The company offers intimate apparel for women, including panties, brassieres, nightwear, and seamless garments, such as shapewear and activewear; undergarments for men; socks for men, women, and children; children's wear; denim clothing item; and women's outerwear such as shirts, dresses, jackets, pants, tops, swimwear, and other products. It also provides leisure wear, active wear, and sportswear. The company offers its products primarily under the 7 For All Mankind, Schiesser, Eminence, Athena, Secret by Athena, Delta Israel, Fix, P.J. Salvage, Splendid, Liabel, Karen Neuburger, and Nearly Nude brands. It also provides its products under the brand names licensed to the company and private labels. The company is also involved in the development, design, marketing, distribution, and sale of branded products in the jeans and over wear clothing and ancillary products. The company sells its products through its own retail shops and outlets, as well as through an online store. Delta Galil Industries Ltd. was incorporated in 1975 and is headquartered in Caesarea, Israel.
Full DELTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.